BEIJING (Reuters) – Chinese military has been given the go-ahead to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials have shown it to be safe and somewhat effective, announced society on monday.
Ad5-nCoV is one of eight vaccine candidates developed by Chinese companies and researchers have approved their transfer to human trials for respiratory disease caused by the new coronavirus. The photo has also been approved for human testing in Canada.
The Central Military Commission of China approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a file. The candidate vaccine was jointly developed by CanSino and the Beijing Biotechnology Institute of the Academy of Military Medical Sciences.
“Ad5-nCoV is currently limited to military use only and its use cannot be extended to a wider vaccination range without the approval of the logistics support department,” said CanSino, referring to the Commission department military center where military use of the vaccine was approved.
Phase 1 and Phase 2 clinical trials have shown that the candidate vaccine can prevent diseases caused by the coronavirus, which has killed half a million people worldwide, but its commercial success cannot be guaranteed, the agency said. society.
No vaccine has yet been approved for commercial use against the disease caused by the new coronavirus, but more than a dozen vaccines from more than 100 candidates worldwide are currently being tested in humans.
Report by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Ana Nicolaci da Costa